Durability of the Diagnosis of Irritable Bowel Syndrome Based on Clinical Criteria

被引:0
作者
Olaitan A. Adeniji
Cody B. Barnett
Jack A. Di Palma
机构
[1] University of South Alabama,The Division of Gastroenterology
[2] College of Medicine,undefined
来源
Digestive Diseases and Sciences | 2004年 / 49卷
关键词
irritable bowel syndrome; diagnosis; clinical criteria; Rome I criteria; Rome II criteria; Manning criteria;
D O I
暂无
中图分类号
学科分类号
摘要
Our purpose was to evaluate the durability of the diagnosis of irritable bowel syndrome (IBS) based on clinical criteria. The study population consisted of a cohort of previously published study patients evaluated for IBS between 1989 and 1992, who met the International Congress of Gastroenterology criteria for IBS. Patients were reinterviewed for cardinal features of IBS, Rome I, Rome II, and Manning criteria 10–13 years after the initial diagnosis. During the observational follow-up period, there were 75 patients, 14 males and 61 females, with a mean age of 47.5 ± 11.3 years (SD; range, 20 to 75 years). Mean time of reinterview after initial diagnosis was 11.8 ± 0.9 years (range, 10 to 13 years). None of the 75 patients had an abdominal condition which could have been mistaken for IBS. Other abdominal conditions diagnosed during this period included diverticulitis (five), uterine fibromyoma (three), and gallbladder disease (three). Sixty-nine patients (92%) did not consider their symptoms as resolved. Thirty-five (46.7%) had repeat structural evaluation of the colon for similar symptoms without any new diagnoses made. Twenty-six (34.7%) and 32 (42.7%) presently meet the Rome II and Rome I criteria for IBS, respectively. Clinicians are advised to use clinical criteria for a specific and durable diagnosis of IBS.
引用
收藏
页码:572 / 574
页数:2
相关论文
共 84 条
[1]  
Manning AP(1978)Towards a positive diagnosis of the irritable bowel Br Med J 2 653-654
[2]  
Thompson WG(1999)Rome II: A multinational consensus document on functional gastrointestinal disorders Gut 45 1-81
[3]  
Heaton KW(1987)Survey of the AGA membership relating to patients with functional gastrointestinal disorders Gastroenterology 92 1282-1284
[4]  
Morris AF(1997)Irritable bowel syndrome: A technical review for practice guideline development Gastroenterology 112 2120-2137
[5]  
Drossman DA(2002)The economic impact of irritable bowel syndrome in a managed care setting J Clin Gastroenterol 3 14-20
[6]  
Corazziari E(2000)Economic burden of irritable bowel syndrome: Proposed strategies to control expenditures Pharmacoeconomics 4 331-338
[7]  
Talley NJ(2001)Management of the irritable bowel syndrome Gastroenterology 120 652-668
[8]  
Mitchell CM(2001)Lotronex Investigator Team: Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 96 2662-2670
[9]  
Drossman DA(2001)Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Alim Pharm Ther 15 1655-1666
[10]  
Drossman DA(1990)Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome Dig Dis Sci 35 1285-1290